HRP20221142T1 - Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću - Google Patents
Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću Download PDFInfo
- Publication number
- HRP20221142T1 HRP20221142T1 HRP20221142TT HRP20221142T HRP20221142T1 HR P20221142 T1 HRP20221142 T1 HR P20221142T1 HR P20221142T T HRP20221142T T HR P20221142TT HR P20221142 T HRP20221142 T HR P20221142T HR P20221142 T1 HRP20221142 T1 HR P20221142T1
- Authority
- HR
- Croatia
- Prior art keywords
- binding protein
- isolated binding
- protein according
- seq
- domain
- Prior art date
Links
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 title 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 title 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 title 1
- 102000023732 binding proteins Human genes 0.000 claims 12
- 108091008324 binding proteins Proteins 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 208000024134 Diffuse cutaneous systemic sclerosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000024883 bone remodeling disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Claims (12)
1. Izolirani vezni protein koji veže TGFβ1, pri čemu je izolirani vezni protein IgG, koji sadrži prvi polipeptidni lanac, drugi polipeptidni lanac, treći polipeptidni lanac i četvrti polipeptidni lanac, naznačen time što
(a) ili se poveznica dodaje navedenom prvom i drugom polipeptidnom lancu, od kojih svaki ima formulu, od N-terminala do C-terminala: (VL domena)-(poveznica1)-(CL domena), ili
(b) poveznica se dodaje navedenom trećem i četvrtom polipeptidnom lancu, od kojih svaki ima formulu od N-terminala do C-terminala: (VH domena)-(poveznica2)-(CH1 domena)-(zglob)-(Fc regija), ili
(c) oboje (a) i (b);
pri čemu:
(i) VL domena svakog od prvog i drugog polipeptidnog lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 3 ili SEQ ID NO: 4; i
(ii) VH domena svakog od trećeg i četvrtog polipeptidnog lanca sadrži aminokiselinsku sekvencu SEQ ID NO: 1 ili SEQ ID NO: 2; i
pri čemu poveznica1, kada je prisutna, i poveznica2, kada je prisutna, sadrže aminokiselinski ostatak ili sekvencu aminokiselina odabranu s popisa koji čine G, GG, GGS, GGGS, i GGGGS.
2. Izolirani vezni protein prema zahtjevu 1, naznačen time što je IgG ljudski IgG4.
3. Izolirani vezni protein prema zahtjevu 2, naznačen time što IgG4 sadrži mutaciju S228P (EU numeriranje).
4. Izolirani vezni protein prema zahtjevu 1, naznačen time što je IgG izotip ljudskog IgG1.
5. Izolirani vezni protein prema zahtjevu 1, naznačen time što svaki od prvog i drugog polipeptidnog lanca neovisno sadrži sekvencu aminokiselina iz SEQ ID NO: 16, 38, 39, 40, 41, 42, ili 43.
6. Izolirani vezni protein prema bilo kojem od zahtjeva 1 do 3 i 5, naznačen time što svaki od trećeg i četvrtog polipeptidnog lanca neovisno sadrži sekvencu aminokiselina iz SEQ ID NO: 17, 18, 56, 57, 58, ili 61.
7. Farmaceutski pripravak naznačen time što sadrži izolirani vezni protein prema bilo kojem od zahtjeva 1-6 i farmaceutski prihvatljivu pomoćnu tvar.
8. Izolirani vezni protein prema bilo kojem od zahtjeva 1-6, ili farmaceutski pripravak prema zahtjevu 7 za upotrebu u liječenju bolesti ili stanja koje proizlazi izravno ili neizravno iz aktivnosti TGFβ1, pri čemu je bolest
(i) fibrozna bolest, rak ili imunološki posredovana bolest;
(ii) bolest pregradnje kostiju;
(iii) bolest bubrega; ili
(iv) difuzna kožna sistemska skleroza.
9. Izolirani polinukleotid naznačen time što sadrži nukleotidnu sekvencu koja kodira izolirani vezni protein prema bilo kojem od zahtjeva 1-6.
10. Vektor naznačen time što sadrži polinukleotid prema zahtjevu 9.
11. Stanica domaćina naznačena time što sadrži vektor prema zahtjevu 10.
12. Postupak za dobivanje izoliranog veznog proteina prema bilo kojem od zahtjeva 1-6, naznačen time što se sastoji od uzgoja stanice domaćina prema zahtjevu 11 pod pogodnim uvjetima za proizvodnju navedenog veznog proteina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128149P | 2015-03-04 | 2015-03-04 | |
| EP16709666.8A EP3265487B1 (en) | 2015-03-04 | 2016-03-03 | Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity |
| PCT/US2016/020780 WO2016141245A1 (en) | 2015-03-04 | 2016-03-03 | Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221142T1 true HRP20221142T1 (hr) | 2022-11-25 |
Family
ID=55524479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221142TT HRP20221142T1 (hr) | 2015-03-04 | 2016-03-03 | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11325970B2 (hr) |
| EP (2) | EP4163299A1 (hr) |
| JP (1) | JP6745275B2 (hr) |
| KR (2) | KR20230116946A (hr) |
| CN (1) | CN107787329B (hr) |
| AR (1) | AR103840A1 (hr) |
| AU (1) | AU2016226098B2 (hr) |
| BR (1) | BR112017018678A2 (hr) |
| CA (1) | CA2978439A1 (hr) |
| DK (1) | DK3265487T3 (hr) |
| ES (1) | ES2927297T3 (hr) |
| HR (1) | HRP20221142T1 (hr) |
| HU (1) | HUE059644T2 (hr) |
| IL (1) | IL254239B2 (hr) |
| LT (1) | LT3265487T (hr) |
| MX (1) | MX2017011252A (hr) |
| PL (1) | PL3265487T3 (hr) |
| PT (1) | PT3265487T (hr) |
| RS (1) | RS63589B1 (hr) |
| RU (1) | RU2728858C2 (hr) |
| SG (2) | SG11201707109XA (hr) |
| SI (1) | SI3265487T1 (hr) |
| TW (1) | TWI733661B (hr) |
| WO (1) | WO2016141245A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| CN109071646A (zh) | 2016-03-11 | 2018-12-21 | 供石公司 | TGFβ1-结合免疫球蛋白及其用途 |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| US20210221849A1 (en) * | 2018-05-10 | 2021-07-22 | Mirabiologics Inc. | Artificial Protein Containing Antigen-Binding Region of Antibody and Being Fused With Physiologically Active Peptide |
| US20220119513A1 (en) * | 2020-06-08 | 2022-04-21 | Zoetis Services Llc | Anti-tgfb antibodies and therapeutic uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
| US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| EP1486560A3 (en) | 1999-04-30 | 2005-02-09 | Cambridge Antibody Technology LTD | Specific antibodies and antibody fragments for TGFBETA1 |
| US20060286105A1 (en) | 2003-04-30 | 2006-12-21 | Steven Ledbetter | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| JP2008513542A (ja) * | 2004-09-22 | 2008-05-01 | ジェンザイム・コーポレイション | 免疫抑制剤の腎毒性を制限するためのＴＧＦ−βアンタゴニストの使用 |
| US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP1874818B1 (en) | 2005-04-22 | 2011-04-13 | Eli Lilly And Company | Tgf beta 1 specific antibodies |
| AU2006330542B2 (en) | 2005-12-23 | 2012-05-24 | Eli Lilly And Company | TGF-beta binding compositions |
| WO2007109254A2 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| KR20090013763A (ko) | 2006-03-23 | 2009-02-05 | 기린 파마 가부시끼가이샤 | 인간 트롬보포이에틴 수용체에 대한 아고니스트 항체 |
| EP3254696A1 (en) * | 2006-10-03 | 2017-12-13 | Genzyme Corporation | Use of tgf beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
| CN102264390A (zh) | 2008-07-02 | 2011-11-30 | 新兴产品开发西雅图有限公司 | Il6免疫治疗 |
| US9409950B2 (en) | 2010-12-23 | 2016-08-09 | Biogen Ma Inc. | Linker peptides and polypeptides comprising same |
| TWI743461B (zh) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| KR102051014B1 (ko) * | 2011-06-03 | 2019-12-04 | 조마 테크놀로지 리미티드 | Tgf-베타에 특이적인 항체 |
| US20140072581A1 (en) | 2012-07-23 | 2014-03-13 | Zymeworks Inc. | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains |
| TWI664979B (zh) | 2013-03-11 | 2019-07-11 | 健臻公司 | 經生物工程之抗-ＴＧＦ-β抗體及抗原結合片段 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
-
2016
- 2016-03-02 TW TW105106247A patent/TWI733661B/zh active
- 2016-03-03 SG SG11201707109XA patent/SG11201707109XA/en unknown
- 2016-03-03 EP EP22180865.2A patent/EP4163299A1/en active Pending
- 2016-03-03 AU AU2016226098A patent/AU2016226098B2/en active Active
- 2016-03-03 EP EP16709666.8A patent/EP3265487B1/en active Active
- 2016-03-03 JP JP2017546179A patent/JP6745275B2/ja active Active
- 2016-03-03 KR KR1020237024971A patent/KR20230116946A/ko active IP Right Grant
- 2016-03-03 RU RU2017134043A patent/RU2728858C2/ru active
- 2016-03-03 DK DK16709666.8T patent/DK3265487T3/da active
- 2016-03-03 BR BR112017018678A patent/BR112017018678A2/pt active Search and Examination
- 2016-03-03 PT PT167096668T patent/PT3265487T/pt unknown
- 2016-03-03 MX MX2017011252A patent/MX2017011252A/es unknown
- 2016-03-03 CN CN201680025633.5A patent/CN107787329B/zh active Active
- 2016-03-03 WO PCT/US2016/020780 patent/WO2016141245A1/en active Application Filing
- 2016-03-03 KR KR1020177027372A patent/KR102560072B1/ko active IP Right Grant
- 2016-03-03 SG SG10201908019U patent/SG10201908019UA/en unknown
- 2016-03-03 HR HRP20221142TT patent/HRP20221142T1/hr unknown
- 2016-03-03 LT LTEPPCT/US2016/020780T patent/LT3265487T/lt unknown
- 2016-03-03 CA CA2978439A patent/CA2978439A1/en active Pending
- 2016-03-03 ES ES16709666T patent/ES2927297T3/es active Active
- 2016-03-03 PL PL16709666.8T patent/PL3265487T3/pl unknown
- 2016-03-03 SI SI201631598T patent/SI3265487T1/sl unknown
- 2016-03-03 HU HUE16709666A patent/HUE059644T2/hu unknown
- 2016-03-03 RS RS20220886A patent/RS63589B1/sr unknown
- 2016-03-03 AR ARP160100560A patent/AR103840A1/es unknown
- 2016-03-03 US US15/555,500 patent/US11325970B2/en active Active
-
2017
- 2017-08-31 IL IL254239A patent/IL254239B2/en unknown
-
2022
- 2022-04-11 US US17/717,967 patent/US11834495B2/en active Active
-
2023
- 2023-10-23 US US18/492,150 patent/US20240117028A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću | |
| JP7179464B2 (ja) | 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用 | |
| EA201991099A1 (ru) | Антитела против cd73 и их применение | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| CN107001468B (zh) | Cd3结合结构域 | |
| KR20190091281A (ko) | 항인간 cd73 항체 | |
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| WO2016191643A4 (en) | Tigit-binding agents and uses thereof | |
| CN106103488A (zh) | 靶向TGFβ抑制 | |
| MX2020011391A (es) | Anticuerpo bcma humanizado y linfocitos t car-bcma. | |
| JP2013515508A5 (hr) | ||
| SI2703486T1 (en) | ANTI-B7-H3 PROTITELO | |
| NZ715896A (en) | Humanized or chimeric cd3 antibodies | |
| JP2013539369A5 (hr) | ||
| JP2018512124A5 (hr) | ||
| RU2021107470A (ru) | Улучшенные вариабельные домены иммуноглобулина | |
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP6247646B2 (ja) | ヒト化抗ｈｍｇｂ１抗体もしくはその抗原結合性断片 | |
| CN111699201A (zh) | 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法 | |
| RU2017104638A (ru) | Нейтрализующие антитела к вирусу гриппа B и пути их применения | |
| JP2017509323A5 (hr) | ||
| JP2021512159A5 (hr) | ||
| KR102058381B1 (ko) | 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법 | |
| RU2017134042A (ru) | ДИМЕРЫ SCFV-FC, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 С ВЫСОКОЙ АФФИННОСТЬЮ, АВИДНОСТЬЮ И СПЕЦИФИЧНОСТЬЮ | |
| US20230416394A1 (en) | Novel conjugate molecules targeting cd39 and tgfbeta |